Paper23901264
Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II, randomized study.
Zarogoulidis K and 12 others. Drug Des Devel Ther, 2013. Cited by 36 papers, by iCite.
Cite this record
ConductScience Library. Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II, randomized study. Papers, record 23901264. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23901264
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II, randomized study.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Interferon-alpha | Major topic |
| Interferon-gamma | Major topic |
| Lung Neoplasms | Major topic |
| Small Cell Lung Carcinoma | Major topic |
| Female | |
| Humans | |
| Immunotherapy | |
| Male | |
| Middle Aged |
Source PubMed
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 3109738 | A phase I study of recombinant interferon gamma administered by s.c. injection three times per week in patients with solid tumours. | Cancer Immunol Immunother | 1987 | https://conductscience.org/library/papers/3109738 | PubMed |
| 2 | 22473169 | Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/22473169 | PubMed |
| 3 | 12438449 | IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. | J Clin Invest | 2002 | https://conductscience.org/library/papers/12438449 | PubMed |
| 4 | 1692761 | Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. | Cancer Res | 1990 | https://conductscience.org/library/papers/1692761 | PubMed |
| 5 | 2432664 | Angiogenic factors. | Science | 1987 | https://conductscience.org/library/papers/2432664 | PubMed |
| 6 | 9210707 | A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. | Cancer | 1997 | https://conductscience.org/library/papers/9210707 | PubMed |
| 7 | 2159055 | Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study. | J Clin Oncol | 1990 | https://conductscience.org/library/papers/2159055 | PubMed |
| 8 | 1371992 | The interferon system. A bird's eye view of its biochemistry. | J Biol Chem | 1992 | https://conductscience.org/library/papers/1371992 | PubMed |
| 9 | 11022927 | Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. | Lancet | 2000 | https://conductscience.org/library/papers/11022927 | PubMed |
| 10 | 8395259 | Interferon-alpha and interferon-gamma combined with chemotherapy: in vitro sensitivity studies in non-small cell lung cancer cell lines. | Anticancer Drugs | 1993 | https://conductscience.org/library/papers/8395259 | PubMed |
| 11 | 8108387 | Cytokine therapeutics: lessons from interferon alpha. | Proc Natl Acad Sci U S A | 1994 | https://conductscience.org/library/papers/8108387 | PubMed |
| 12 | 3296212 | Alfa interferon: combinations with other antineoplastic modalities. | Semin Oncol | 1987 | https://conductscience.org/library/papers/3296212 | PubMed |
| 13 | 6861260 | Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. | Cancer Chemother Pharmacol | 1983 | https://conductscience.org/library/papers/6861260 | PubMed |
| 14 | 7964947 | Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. | J Clin Oncol | 1994 | https://conductscience.org/library/papers/7964947 | PubMed |
| 15 | 7505989 | [Interferon therapy of the lung and locoregional therapy in pulmology]. | Wien Med Wochenschr | 1993 | https://conductscience.org/library/papers/7505989 | PubMed |
| 16 | 9799713 | Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. | Semin Immunol | 1998 | https://conductscience.org/library/papers/9799713 | PubMed |
| 17 | 23386565 | Cancer statistics for African Americans, 2013. | CA Cancer J Clin | 2013 | https://conductscience.org/library/papers/23386565 | PubMed |
| 18 | 16293867 | Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/16293867 | PubMed |
| 19 | 8882986 | Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: a randomized trial. | Lung Cancer | 1996 | https://conductscience.org/library/papers/8882986 | PubMed |
| 20 | 8624296 | Selective suppression of cytokine secretion in patients with small-cell lung cancer. | Ann Oncol | 1995 | https://conductscience.org/library/papers/8624296 | PubMed |
Cited by31
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 36 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41220920 | IFN-gamma in the tumor microenvironment: dual roles in cancer progression and therapy. | EXCLI J | 2025 | https://conductscience.org/library/papers/41220920 | PubMed |
| 40473974 | The current and emerging immunotherapy paradigm in small-cell lung cancer. | Nat Cancer | 2025 | https://conductscience.org/library/papers/40473974 | PubMed |
| 36945221 | Molecular docking analysis of VEGF with compounds from tomato. | Bioinformation | 2022 | https://conductscience.org/library/papers/36945221 | PubMed |
| 35734400 | Homologous Recombination Pathway Alternation Predicts Prognosis of Colorectal Cancer With Chemotherapy. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35734400 | PubMed |
| 34685400 | Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer. | Life (Basel) | 2021 | https://conductscience.org/library/papers/34685400 | PubMed |
| 34295691 | Immunotherapy in small cell lung cancer: one step at a time: a narrative review. | Transl Lung Cancer Res | 2021 | https://conductscience.org/library/papers/34295691 | PubMed |
| 32766139 | Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC). | Front Oncol | 2020 | https://conductscience.org/library/papers/32766139 | PubMed |
| 32194311 | Advances and challenges in immunotherapy of small cell lung cancer. | Chin J Cancer Res | 2020 | https://conductscience.org/library/papers/32194311 | PubMed |
| 32102135 | [Research Progress of Immunotherapy and Prognostic Markers in Small Cell Lung Cancer]. | Zhongguo Fei Ai Za Zhi | 2020 | https://conductscience.org/library/papers/32102135 | PubMed |
| 31781314 | The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature. | Can Respir J | 2019 | https://conductscience.org/library/papers/31781314 | PubMed |
| 31632972 | Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma. | Front Cell Dev Biol | 2019 | https://conductscience.org/library/papers/31632972 | PubMed |
| 31619019 | Technological and Therapeutic Advances in Advanced Small Cell Lung Cancer. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31619019 | PubMed |
| 30643969 | ZWINT is the next potential target for lung cancer therapy. | J Cancer Res Clin Oncol | 2019 | https://conductscience.org/library/papers/30643969 | PubMed |
| 30637710 | The role of immunotherapy in small cell lung cancer. | Clin Transl Oncol | 2019 | https://conductscience.org/library/papers/30637710 | PubMed |
| 29896282 | Aerosol Immunotherapy with or without Cisplatin for metastatic lung cancer non-small cell lung cancer disease: In vivo Study. A more efficient combination. | J Cancer | 2018 | https://conductscience.org/library/papers/29896282 | PubMed |
| 28641701 | [Recent Advances and Future Strategies for Small Cell Lung Cancer]. | Zhongguo Fei Ai Za Zhi | 2017 | https://conductscience.org/library/papers/28641701 | PubMed |
| 28456992 | Progress and challenges in the treatment of small cell lung cancer. | Med Oncol | 2017 | https://conductscience.org/library/papers/28456992 | PubMed |
| 28123595 | Research progress in the treatment of small cell lung cancer. | J Cancer | 2017 | https://conductscience.org/library/papers/28123595 | PubMed |
| 27354668 | The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. | Oncologist | 2016 | https://conductscience.org/library/papers/27354668 | PubMed |
| 27076850 | Tyrosine Kinase Inhibitors for the Elderly. | J Cancer | 2016 | https://conductscience.org/library/papers/27076850 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| IFNA1 | 3439 | PubTator's text mining | https://conductscience.org/library/genes/3439 | NCBI Gene |
| IFNB1 | 3456 | PubTator's text mining | https://conductscience.org/library/genes/3456 | NCBI Gene |
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| IL2 | 3558 | PubTator's text mining | https://conductscience.org/library/genes/3558 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23901264
GET https://conductscience.org/api/papers/v1/23901264/references?page=2